Navigation Links
Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
Date:9/28/2011

ANAHEIM, Calif., Sept. 28, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced preliminary operating metrics for its third quarter ending September 30, 2011. The Company announced the estimated metrics in conjunction with the Jeffries Global Healthcare Conference in London, where Don M. Bailey, President and Chief Executive Officer of Questcor, presented on Wednesday, September 28, 2011, at 8:00 a.m. BT, 3:00 a.m. ET.  To listen to the audio web cast of the presentation, please visit www.questcor.com.  The replay will be available for 90 days after the event.

For the quarter ending September 30, 2011, the Company provided the following preliminary estimated operating metrics:

  • Based on internal Company data through September 26, 2011:
    • New, paid prescriptions of the Company's principal drug, H.P. Acthar® Gel (Acthar), for the treatment of exacerbations of multiple sclerosis (MS) during the full third quarter are expected to exceed 850, up over 160% from the year ago period.
    • New, paid prescriptions for nephrotic syndrome (NS) are expected to exceed 55.  
    • New, paid prescriptions for infantile spasms (IS) are expected to exceed 105.
  • Vials of Acthar, shipped during the quarter are expected to exceed 2,750, up over 45% from the year ago period.

During the third quarter, the Company has not repurchased any of its common stock. Prior repurchases have used over $78 million since this effort began in 2008.  As of September 26, 2011, Questcor had 62.7 million shares of common stock outstanding, with 4.3 million shares remaining under its common stock repurchase program.

As of September 26, 2011, Questcor's cash, cash equivalents and short-term
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on September 28, 2011
2. Questcor Provides Updated New Paid Prescription Trends
3. UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
4. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
5. Questcor to Report Second Quarter 2011 Earnings and Conduct Conference Call on July 26, 2011
6. Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
7. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
8. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
9. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
10. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
11. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SOUTH SAN FRANCISCO , July 29, 2015 /PRNewswire/ ... a monoclonal antibody company focused on developing innovative therapies ... with a focus on oncology, announced today that the ... company,s investigational new drug (IND) application for KB003, an ... leukemia (CMML), and that the IND is now active. ...
(Date:7/29/2015)... July 27, 2015 Research and Markets ... the "Global Neurostimulation Devices Market 2015" ... forecast the global neurostimulation devices market to grow ... 2014-2019. The report, Global Neurostimulation Devices ... in-depth market analysis with inputs from industry experts. ...
(Date:7/29/2015)... 2015  ViaCyte, Inc., a privately-held regenerative medicine company with the ... in clinical trials, today announced the opening of a second site ... afety, T olerability, and E fficacy of VC-01™ Combination ... site, which is the first in Canada , ... Edmonton , Alberta.  The lead ...
Breaking Medicine Technology:KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5Global Neurostimulation Devices Market 2015-2019 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4
... DIEGO, March 30, 2012 Optimer Pharmaceuticals, Inc. (NASDAQ: ... from a post-hoc subgroup analysis of the company,s two ... with Clostridium difficile -associated diarrhea (CDAD) had higher ... when treated with DIFICID® (fidaxomicin) tablets compared to oral ...
... March 30, 2012 Evergreen Hospital – one of ... the first robot-assisted single-incision gallbladder removal in the Washington ... just approved by the FDA. Evergreen,s Dr. ... a 66-year-old man and a 33-year-old woman – making ...
Cached Medicine Technology:Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD) 2Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD) 3Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD) 4Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD) 5Evergreen Hospital Performs Region's First Single-Site Gallbladder Removal Using da Vinci Robot 2Evergreen Hospital Performs Region's First Single-Site Gallbladder Removal Using da Vinci Robot 3
(Date:7/29/2015)... , ... July 29, 2015 , ... ... on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that ... and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline ...
(Date:7/29/2015)... MA (PRWEB) , ... July 29, 2015 , ... Ticket ... Gillette Stadium featuring Brazil vs. USA . , The international soccer ... it has grown exponentially and now on September 8th, one of the world’s greatest ...
(Date:7/29/2015)... ... July 29, 2015 , ... Topical BioMedics, ... Topricin® Pain Relief and Healing Cream designated as the nonprofit’s natural pain reliever ... actively addressing Line of Duty Deaths (LODD) and the high rate of pain ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to The Spirits Business ... is directly responsible for stimulating and perpetuating alcohol use disorders. Humans have the same ... of the National academy of Sciences, and has given researchers inklings to explore Rsu1 ...
(Date:7/29/2015)... ... July 29, 2015 , ... On July 26th the ... the FDA for nicotine laced liquid products. Their report says cigarette use has ... E-Cigarettes are particularly troublesome to addiction professionals as many of the candy flavors ...
Breaking Medicine News(10 mins):Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 2Health News:Cheap USA vs. Brazil Tickets at Gillette Stadium: Ticket Down Cuts Presale Ticket Prices for Brazil vs. USA Men's National Soccer Team (USMNT) at Gillette Stadium 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 2Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 3Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 4Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 5Health News:Topical BioMedics Partners with 555 Fitness: Topricin® Designated as the Nonprofit’s Natural Pain Reliever of Choice 6Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 2Health News:Harbor Village Urges South Florida Residents to Abstain from the Use of E Cigarettes 3
... older age results in grave consequences. People who are ... diet and exercise. This increases their physical function// and ... to a loss of functional independence in the community, ... T. Villareal from Washington University School of Medicine in ...
... the Liverpool University suggests that men are more aware of ... most fertile. The researchers felt that men// become more jealous ... are at their most fertile. ,The Evolution and ... suggested those with ovulating partners were vary wary of the ...
... Researchers have found a novel way to verify that ... surgery. The detailed report is published in the May ... a newly explored region of the electromagnetic spectrum--the terahertz ... removed tissue margins were clear of cancer, with good ...
... have said that The World Bank did not aid the ... promised sum of $500 million// to combat malaria. In addition, ... adequate infrastructure and resources in hand to see an initiative ... that medicines used for the program were ineffective in meeting ...
... the process of updating the pediatric growth charts. The outdated ... present// the rates at which the babies are supposed to ... old charts are said to be based on growth patterns ... data from breast-fed babies who tend to grow slower, reports ...
... Recent studies have suggested that people over 50 are under ... of loneliness most// of the time. ,Feeling lonely ... hypertension, following closely behind more commonly publicized risk factors like ... that loneliness has the potential to add 30 points to ...
Cached Medicine News:Health News:Jealousy In Men Peaks When Partners Are Most Fertile 2Health News:Terahertz Imaging Promises To Revolutionize Breast Cancer Treatments 2Health News:Loneliness to Lead to Hypertension 2
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... These hygroscopic condenser humidifiers (HCH) capture ... return them in the inspired gas. Small ... provide bacteriostatic and hygroscopic benefits. Depending on ... adult or small-volume model., ,The adult ...
Medicine Products: